Strategic Advisors LLC trimmed its stake in Elevance Health, Inc. (NYSE:ELV – Free Report) by 50.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,000 shares of the company’s stock after selling 1,000 shares during the quarter. Strategic Advisors LLC’s holdings in Elevance Health were worth $520,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in ELV. Bank & Trust Co acquired a new position in shares of Elevance Health in the second quarter worth $27,000. Palisade Asset Management LLC acquired a new position in shares of Elevance Health in the first quarter worth $28,000. Opal Wealth Advisors LLC acquired a new position in Elevance Health in the second quarter valued at $28,000. Strategic Financial Concepts LLC acquired a new position in Elevance Health in the second quarter valued at $30,000. Finally, Beaird Harris Wealth Management LLC acquired a new position in Elevance Health in the fourth quarter valued at $32,000. 89.24% of the stock is owned by institutional investors and hedge funds.
Elevance Health Stock Down 0.0 %
Shares of NYSE ELV traded down $0.09 on Thursday, hitting $493.42. The company had a trading volume of 334,856 shares, compared to its average volume of 1,016,499. Elevance Health, Inc. has a 12-month low of $435.99 and a 12-month high of $567.26. The business has a 50 day moving average of $533.40 and a two-hundred day moving average of $529.32. The company has a quick ratio of 1.49, a current ratio of 1.49 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $114.68 billion, a P/E ratio of 18.65, a PEG ratio of 1.17 and a beta of 0.82.
Elevance Health Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 25th. Shareholders of record on Tuesday, September 10th were paid a dividend of $1.63 per share. This represents a $6.52 annualized dividend and a yield of 1.32%. The ex-dividend date was Tuesday, September 10th. Elevance Health’s payout ratio is currently 24.64%.
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on ELV shares. Stephens reiterated an “overweight” rating and issued a $615.00 target price on shares of Elevance Health in a research note on Thursday, September 5th. TD Cowen dropped their target price on Elevance Health from $624.00 to $589.00 and set a “buy” rating for the company in a research note on Friday, July 19th. Royal Bank of Canada upped their target price on Elevance Health from $575.00 to $585.00 and gave the company an “outperform” rating in a research note on Thursday, July 18th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $600.00 target price on shares of Elevance Health in a research note on Tuesday, October 1st. Finally, Morgan Stanley started coverage on Elevance Health in a research report on Monday, June 24th. They set an “overweight” rating and a $643.00 price target for the company. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $604.29.
Insider Buying and Selling at Elevance Health
In other Elevance Health news, Director Robert L. Dixon, Jr. sold 305 shares of the company’s stock in a transaction that occurred on Friday, July 19th. The stock was sold at an average price of $506.76, for a total transaction of $154,561.80. Following the sale, the director now owns 9,721 shares in the company, valued at $4,926,213.96. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, CEO Gail Boudreaux sold 34,000 shares of the stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $500.98, for a total value of $17,033,320.00. Following the completion of the transaction, the chief executive officer now directly owns 126,709 shares of the company’s stock, valued at $63,478,674.82. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Robert L. Dixon, Jr. sold 305 shares of the stock in a transaction that occurred on Friday, July 19th. The stock was sold at an average price of $506.76, for a total value of $154,561.80. Following the completion of the transaction, the director now directly owns 9,721 shares of the company’s stock, valued at $4,926,213.96. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,058 shares of company stock worth $17,588,116 over the last quarter. 0.35% of the stock is owned by corporate insiders.
Elevance Health Profile
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
Featured Articles
- Five stocks we like better than Elevance Health
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- How is Compound Interest Calculated?
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- How to Invest in Biotech Stocks
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.